

# Shiv Srivastava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1923602/publications.pdf>

Version: 2024-02-01

52  
papers

3,296  
citations

279798

23  
h-index

223800

46  
g-index

54  
all docs

54  
docs citations

54  
times ranked

3979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Liê€Fraumeni syndrome. <i>Nature</i> , 1990, 348, 747-749.	27.8	1,156
2	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. <i>European Urology</i> , 2015, 68, 123-131.	1.9	281
3	A long noncoding RNA connects c-Myc to tumor metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18697-18702.	7.1	258
4	Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 1996, 156, 1511-1516.	0.4	218
5	Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer. <i>Journal of Urology</i> , 1995, 154, 414-421.	0.4	161
6	Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. <i>Oncogene</i> , 1998, 16, 265-272.	5.9	115
7	Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. <i>International Journal of Cancer</i> , 2001, 92, 322-328.	5.1	96
8	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 1997, 79, 952-962.	4.1	72
9	TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. <i>American Journal of Epidemiology</i> , 2017, 186, 1352-1361.	3.4	60
10	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	57
11	Clinical potential of the ERG oncoprotein in prostate cancer. <i>Nature Reviews Urology</i> , 2012, 9, 131-137.	3.8	56
12	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1255.	4.1	50
13	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377-382.		46
14	Allelic loss on chromosome 6Q in primary prostate cancer. , 1999, 84, 331-335.		46
15	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 810-822.	2.3	45
16	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 406-410.	3.9	45
17	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. <i>Urology</i> , 2016, 89, 69-75.	1.0	43
18	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	1.9	32

#	ARTICLE	IF	CITATIONS
19	A novel human cancer culture model for the study of prostate cancer. <i>Oncogene</i> , 2001, 20, 8036-8041.	5.9	31
20	Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. <i>Oncotarget</i> , 2015, 6, 15137-15149.	1.8	29
21	Mutations of the p16 gene product are rare in prostate cancer. , 1997, 30, 188-194.		28
22	Ethnicity and ERG frequency in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 125-131.	3.8	28
23	The center for prostate disease research (CPDR): A multidisciplinary approach to translational research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 562-569.	1.6	27
24	Methylation of the <i>PMEPA1</i> gene, a negative regulator of the androgen receptor in prostate cancer. <i>Epigenetics</i> , 2014, 9, 918-927.	2.7	25
25	Synchronous Bilateral Testicular Tumour: Nonseminomatous Germ Cell Tumours and Contralateral Benign Tumours. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 389-392.	1.4	24
26	Predominance of ERG-negative high-grade prostate cancers in African American men. <i>Molecular and Clinical Oncology</i> , 2014, 2, 982-986.	1.0	24
27	Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF- $\beta$ 2 from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer. <i>Genes and Cancer</i> , 2019, 10, 134-149.	1.9	24
28	Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. <i>Journal of Translational Medicine</i> , 2015, 13, 54.	4.4	23
29	p53-dependent induction of heat shock protein 27 (HSP27) expression. <i>International Journal of Cancer</i> , 2000, 88, 191-194.	5.1	21
30	Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. <i>Oncotarget</i> , 2016, 7, 22791-22806.	1.8	19
31	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. <i>Scientific Reports</i> , 2017, 7, 1109.	3.3	17
32	Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. <i>European Urology Focus</i> , 2018, 4, 818-824.	3.1	16
33	Detection of Head and Neck Cancer Based on Longitudinal Changes in Serum Protein Abundance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1665-1672.	2.5	16
34	Prognostic features of Annexin A2 expression in prostate cancer. <i>Pathology</i> , 2021, 53, 205-213.	0.6	15
35	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. <i>Genes and Cancer</i> , 2017, 7, 394-413.	1.9	14
36	Statistical Modeling Using Preoperative Prognostic Variables in Predicting Extracapsular Extension and Progression after Radical Prostatectomy for Prostate Cancer. <i>Military Medicine</i> , 1998, 163, 615-619.	0.8	12

#	ARTICLE	IF	CITATIONS
37	ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 368-379.	3.4	12
38	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. <i>Scientific Reports</i> , 2022, 12, 5404.	3.3	10
39	ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. <i>Molecular and Clinical Oncology</i> , 2015, 3, 23-30.	1.0	8
40	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. <i>Genes and Cancer</i> , 2014, 5, 273-284.	1.9	8
41	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. <i>Nature Communications</i> , 2022, 13, 1361.	12.8	8
42	New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1703-1709.	2.8	5
43	Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors. <i>Journal of Cancer</i> , 2015, 6, 490-501.	2.5	4
44	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 1997, 79, 952-962.	4.1	4
45	Mutations of the p16 gene product are rare in prostate cancer. <i>Prostate</i> , 1997, 30, 188-194.	2.3	2
46	Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>European Urology</i> , 2017, 71, 692.	1.9	1
47	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377.		1
48	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. <i>International Journal of Cancer</i> , 1997, 71, 377-382.	5.1	1
49	<i>PMEPA1</i> gene isoforms to indicate disease progression in solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16580-e16580.	1.6	1
50	Abstract 2074: Germline mutation landscape of all DNA repair genes in African American prostate cancer patients. , 2021, , .		0
51	Abstract 2526: PMEPA1 gene isoforms indicated aggressive disease progression in non-prostate solid tumors. , 2021, , .		0
52	Identification of an Orphan 7TM Receptor PSGR as a Functional Intracellular GPCR. <i>FASEB Journal</i> , 2008, 22, 722.6.	0.5	0